| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Prospective Study |
| Article Title |
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lorenzo Antonuzzo, Elisa Giommoni, Davide Pastorelli, Tiziana Latiano, Ida Pavese, Domenico Azzarello, Michele Aieta, Ilaria Pastina, Francesca Di Fabio, Alessandro Bertolini, Domenico Cristiano Corsi, Selene Mogavero, Valentina Angelini, Mario Pazzagli and Francesco Di Costanzo |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lorenzo Antonuzzo, MD, Medical Oncology, Elisa Giommoni, Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Viale Pieraccini 17, 50139 Firenze, Italy. lorenzo.antonuzzo@gmail.com
|
| Key Words |
Bevacizumab; Colorectal neoplasms; Chemotherapy; anti- Vascular endothelial growth factor; XELOX |
| Core Tip |
Combined with fluorouracil-based chemotherapy, bevacizumab significantly improved survival, compared to placebo, in previously untreated metastatic colorectal cancer (mCRC) patients and in second-line treatment. In this perspective, the aim of this multicentric, prospective, open-label, single arm, non comparative study (the OBELIX study) was to confirm previous results on the positive outcome of bevacizumab/XELOX treatment in locally advanced CRC (aCRC) or mCRC patients in Italy. Our findings confirm the clinical benefit provided by bevacizumab plus XELOX in terms of proliferation-free survival, without the appearance of new areas of toxicity and an overall acceptable safety profile.
|
| Publish Date |
2015-06-20 17:38 |
| Citation |
Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i23/7281.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i23.7281 |
